-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Dogwood Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- Dogwood Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.3M, a 80.6% decline year-over-year.
- Dogwood Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$5.82M, a 8.99% increase year-over-year.
- Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$5.45M, a 55.8% increase from 2022.
- Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$12.3M, a 21.3% increase from 2021.
- Dogwood Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$15.6M, a 56.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)